Autolus Therapeutics plc has reported its financial results for the second quarter of 2025. The company's Q2 2025 AUCATZYL® net product revenue was $20.9 million, contributing to a total of $29.9 million for the first six months of 2025. The net loss for the three months ended June 30, 2025, was $47.9 million, an improvement from the $58.3 million net loss in the same period of 2024. The basic and diluted net loss per ordinary share was $(0.18), compared to $(0.22) in the prior year. Cash, cash equivalents, and marketable securities totaled $454.3 million as of June 30, 2025, down from $588.0 million at the end of 2024. This decrease was mainly due to net cash used in operating activities and a delayed cash receipt of about $21.7 million in R&D tax credit expected from the UK HMRC. The company has recently received conditional marketing authorization for AUCATZYL® from both the U.K. Medicines and Healthcare products Regulatory Agency and the European Commission. Additionally, Autolus is on track to initiate Phase 2 pivotal clinical trial in lupus nephritis and a Phase 1 clinical trial in progressive forms of multiple sclerosis by the end of 2025. Autolus has stated that it is well-capitalized to support the launch and commercialization of obe-cel in r/r B-ALL and to obtain data in the ongoing trials.